CAJ | 학술논문

目的：探讨经导管肝动脉化疗栓塞（TACE）联合经皮微波消融术（MWA）治疗中晚期肝癌预后的影响因素。方法2011年1月-2012年7月，64例中晚期肝癌患者行TACE联合MWA治疗，收集14项可能影响预后的因素作回顾性单因素与多因素分析。单因素分析采用Kaplan-Meier模型及Log-rank检验，多因素分析采用Cox比例风险模型。结果64例中晚期肝癌患者治疗后1、1.5、2年总生存率分别为75.8%、48.4%、33.9%。单因素分析及Cox回归分析结果显示肿瘤大小、肿瘤数目、门静脉癌栓、血清AFP值、肿瘤期别、服用索拉菲尼等6项因素与预后有关。结论肿瘤大小、肿瘤数目、门静脉癌栓、血清AFP值、肿瘤期别是影响介入综合治疗预后的危险因素，服用索拉菲尼是影响预后的保护性因素。
목적：탐토경도관간동맥화료전새（TACE）연합경피미파소융술（MWA）치료중만기간암예후적영향인소。방법2011년1월-2012년7월，64례중만기간암환자행TACE연합MWA치료，수집14항가능영향예후적인소작회고성단인소여다인소분석。단인소분석채용Kaplan-Meier모형급Log-rank검험，다인소분석채용Cox비례풍험모형。결과64례중만기간암환자치료후1、1.5、2년총생존솔분별위75.8%、48.4%、33.9%。단인소분석급Cox회귀분석결과현시종류대소、종류수목、문정맥암전、혈청AFP치、종류기별、복용색랍비니등6항인소여예후유관。결론종류대소、종류수목、문정맥암전、혈청AFP치、종류기별시영향개입종합치료예후적위험인소，복용색랍비니시영향예후적보호성인소。
Objective To investigate the prognostic factors affecting the outcome of patients with intermediate-advanced hepatocellular carcinoma (HCC) receiving transcatheter arterial chemoembolization (TACE) combined with percutaneous microwave ablation (MWA). Methods During the period from January 2011 to July 2012 at authors’ hospital, a total of 64 patients with intermediate-advanced HCC were treated with TACE together with MWA. Fourteen potential variables which might affect the prognosis were colleted and were retrospectively analyzed. Kaplan-Meier model and log-rank test were used for single factor analysis, while Cox regression model was used for multiple factor analysis. Results The one-year, 1.5-year and 2-year overall survival rates were 75.8%, 48.4% and 33.9%, respectively. Single factor analysis and Cox regression analysis indicated that six factors, i.e. tumor size, number of tumors, portal vein tumor thrombus, serum α-fetoprotein level, tumor staging and oral administration of sorafenib, bore a relationship to the prognosis. Conclusion The tumor size, number of tumors, portal vein tumor thrombus, serum α-fetoprotein level and tumor staging are risk factors influencing the results of interventional comprehensive therapy , while oral administration of sorafenib is a protective factor for the prognosis.